An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Barclays PLC increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% in the 3rd quarter ...

Sutro Biopharma's valuation remains compelling despite recent market hits, with optimism for a turnaround. Click here to find ...

Jane Street Group LLC cut its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 6.8% during ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...